Innovation – Open view page

General information

Innovation ID553
Version ID423
Innovation TitleChickpea inbred variety ICCV 97105 for cultivation in mid-altitudes in Malawi, Kenya, and Tanzania
Innovation description ICCV 97105 is a medium duration desi variety adapted across the medium and high-altitude semi arid environments. This variety is relatively less susceptible to pod sucking bugs and to pod borers, and has tolerance to leaf diseases and wilt. It flowers in 35-44 days and matures in 125-142 days, with yield potential of 2.6 mt/ha. This variety will potentially contribute to SDG Goals 1,2 and 3.
Reporting Staff NVPR Ganga Rao (ICRISAT)
Year (Reporting)2020
Reporting statusApproved
Innovation TypeGenetic (variety and breeds)
Number of varieties1

Stage reached

Stage of InnovationStage 3: available/ ready for uptake
Year (Stage)2020
Stage DescriptionICCV 97105 was released on July 24, 2020 for cultivation in the medium altitudes of Malawi. It has potential spillover effects in Kenya, and Tanzania.
Has a lead organizationyes
Lead OrganizationMinistry of Agriculture Irrigation and Water Development, Department of Agricultural Research Services
Top 5 contributorsInternational Crops Research Institute for the Semi-Arid Tropics

Contributions and mapping

All partners
Main CRP CGIAR Research Program on Grain Legumes and Dryland Cereals
Flagship project FP4-Variety and Hybrid Development
Cluster FP4-3-Product testing and release
Other CRPs-Flagships-Clusters

Scope

Geographic scopeNational
Regions
CountriesMalawi,Kenya,United Republic of Tanzania

Targeted outcomes

Main Sub-IDO Enhanced genetic gain
Other Sub-IDO Closed yield gaps through improved agronomic and animal husbandry practices
Other Sub-IDO Reduced production risk

Evidences

EvidencesList of crop varieties and hybrids released in 2020 co-developed by ICRISAT and CRP-GLDC with partners
[https://mel.cgiar.org/uploads/relatedfiles/jhF3fH3GLzIx9UvsOqbzlMPwA0MDgf.xlsx]

Linked Elements

Milestones6814-172-37920 - New suite of resilient varieties released by NARS partners. (Phase 1 investments start being released)
Outcome Impact Case
Policy